Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894343 · ClinicalTrials.gov registry record · Phase 1
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
A Phase 1 study of Parkinson's Disease, sponsored by MeiraGTx.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT05894343 is a Phase 1 study of Parkinson's Disease that is active but no longer recruiting, run by MeiraGTx. The registered enrollment target is 13 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05894343, a Phase 1 study of Parkinson's Disease, is active but no longer recruiting, sponsored by MeiraGTx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
Conditions Studied
Interventions
- GENETIC AAV-GAD
Study Locations (6)
New York
- Weill Cornell Medicine - New York
- Columbia University Irving Medical Center - New York
Connecticut
- Yale University - New Haven
Michigan
- Henry Ford West Bloomfield Hospital - West Bloomfield
Pennsylvania
- Thomas Jefferson University - Philadelphia
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894343
The ClinicalTrials.gov registry entry for NCT05894343 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The listed sponsor is MeiraGTx, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which AAV-GAD is the first listed.
NCT05894343 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, Connecticut, Michigan.
Frequently Asked Questions
What is clinical trial NCT05894343 about?
NCT05894343 is a clinical study titled "Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease". The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
What is the current status of trial NCT05894343?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-05-19. Estimated completion is 2029-10.
What conditions does trial NCT05894343 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT05894343?
The interventions under investigation include: AAV-GAD (GENETIC).
Who is sponsoring clinical trial NCT05894343?
This trial is sponsored by MeiraGTx, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05894343 being conducted?
This trial has 6 study locations across Connecticut, Michigan, New York, Pennsylvania, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.